The global thyroid gland disorder treatment market represents a highly competitive and fragmented landscape.This is mainly due to the presence of numerous small and large players in the market, says Transparency Market Research.These players are relying on several strategies such as partnership agreements, regional expansions, brand awareness activities, and increase product profiliration in order to gain a competitive edge in the market.In addition, increasing FDA approval of novel drug patent for the treatment of thyroid gland disorder treatment market is expected to fuel rivalry among players in the coming years.In june 2018,  Hutchison China MediTech Limited, a key players in the global throid gland disorder treatment market has  initiated a Phase Ib/II proof-of-concept study of sulfatinib in pancreatic neuroendocrine.Once developed and successfully tested the drug is expected to treat tumors and biliary tract cancer efficiently.This is expected to fuel tyroid gland disorder market in the coming years.Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=3113In the same year, another player called AmpliPhi Biosciences Corporation presented a AB-PA01 Bacteriophage Therap.
Antidepressants are drugs commonly used to treat neurological and chronic disorders which include sleep disorders, dysthymia, anxiety disorders, eating disorders, migraine, and attention-deficit hyperactivity disorder (ADHD).The most intriguing part is these medicines or drugs can be consumed alone or can be combined with any other medicine as well.The most dominant group of antidepressants includes:Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)Selective Serotonin Reuptake Inhibitors (SSRIs)Tricyclic Antidepressants (TCAs)Reversible Inhibitors of Monoamine Oxidase A (RIMAs)Tetracyclic Antidepressants (TeCAs)Monoamine Oxidase Inhibitors (MAOIs)Noradrenergic and specific serotonergic antidepressants (NaSSAs)Insomnia is a sleep disorder and antidepressants can provide effective relief from this medical condition.These groups perform key role in treating insomnia and other sleep disorders.One can buy sleeping pills online to get rid of insomnia without getting addicted to it.Antidepressants work on the mechanism of regulating HPA also known as Hypothalamic-Pituitary-Adrenal Axis which is a joint set of interactions between the hypothalamus, pituitary gland and adrenal gland.This complex set forms a neuroendocrine system and functions on stress and anxiety.Overactivity in the brain or abnormalities in the functioning of this HPA axis stimulates stress and depressive signs.
Market HighlightsCarcinoid tumor is a type of the neuroendocrine tumor.The most common site of carcinoid tumors is the GI (gastrointestinal) tract and the lungs.However, it can also be developed in pancreas, testicles, and ovaries.According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract.However, lack of awareness, high treatment cost and related side effects may hamper the market growth during the forecast period.The serology segment is sub-segmented into blood test, urine test, molecular test, and others.
Market HighlightsCarcinoid tumor is a type of the neuroendocrine tumor.The most common site of carcinoid tumors is the GI (gastrointestinal) tract and the lungs.However, it can also be developed in pancreas, testicles, and ovaries.According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract.However, lack of awareness, high treatment cost and related side effects may hamper the market growth during the forecast period.The serology segment is sub-segmented into blood test, urine test, molecular test, and others.
Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Carcinoid Tumor Market Research Report – Global Forecast till 2023” Gives industry size, top players and worldwide demandMarket Scenario:Carcinoid tumor is a type of the neuroendocrine tumor.The most common site of carcinoid tumors is GI (gastrointestinal) tract and lungs.According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract.Key Players Novartis AG (Europe)Amgen Inc. (U.S.)Boehringer Ingelheim GmbH (Europe)AVEO Pharmaceuticals, Inc. (U.S.)Chiasma, Inc. (U.S.)Aegis Therapeutics, LLC (U.S.)CRINETICS PHARMACEUTICALS (U.S.)Delcath Systems Inc. (U.S.)Exelixis, Inc. (U.S.)Regional AnalysisAmerica dominates the global carcinoid tumor market owing to a well-developed healthcare sector and huge patient population.Apart from this, increasing healthcare expenditure and presence of developed economies within the region are adding fuel to the growth of the market in America.Europe is the second leading region in the global carcinoid tumor market, which is followed by Asia Pacific.Availability of funds for research, huge patient population and government support for research & development are projected to drive the market.
Global Appendiceal Cancer Treatment Market size was valued US$ XX Bn.Global Appendiceal Cancer Treatment MarketThe report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.Definition:Appendiceal Cancer is the cancer of the appendix which is an organ connected to the colon at the beginning of the large intestine.It is often discovered during surgery for appendicitis or due to acute pain in the appendix.Market Dynamics:The function of the appendix is not known but it is said to help with the immunity as it stores good bacteria.In June 2019, Pfizer Inc. announced to acquire BioPharma Inc. to foster growth in the treatment segment.Market Segmentation:Based on the type, neuroendocrine tumors are the most commonly found among appendiceal cancer and are generally discovered or diagnosed after the appendix removal surgery.These tumors are more among the women aged above forty years.It is followed by systematic chemotherapy or targeted therapy for complete eradication of the tumor cells.Region-wise Analysis:The appendiceal cancer treatment market is expected to be dominant in North America during the forecast period due to its highly developed healthcare infrastructure, advancing R, and adoption of new treatments prior to any other regions will result in the growth of the appendiceal cancer treatment market in North America.Competitive Landscape:The competitive landscape section in the Appendiceal Cancer Treatment market offers a deep dive into the profiles of the leading players operating in the global market landscape.
Global Somatostatin Analogs Market Research Report, By Types (Octreotide, Lanreotide, and Pasireotide), By Applications (Neuroendocrine Tumor (NET), Acromegaly and others), By Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2025Global Market – OverviewAccording to MRFR analysis, Somatostatin Analogs Market is expected to register a CAGR of 6.8% during the forecast period of 2019 to 2025 and is anticipated to reach USD 8,640 Million by 2025.The growth of the global somatostatin analogs market is driven by various factors such as increasing research & development activity in the somatostatin analogs market and increasing numbers of players involved in the development of generic versions of somatostatin analogs.In addition, the rising incidence rate of the NETs; and increasing efforts by government bodies and public and private organizations to increase awareness about Acromegaly are some of the other factors for the growth of the somatostatin analogs market.Key PlayersNovartis AG (Switzerland)Ipsen Pharma (France)Fresenius Kabi (Germany)Peptron (South Korea)Pfizer Inc. (US)Teva Pharmaceuticals Inc. (Israel)Avail a Free [email protected] https://www.marketresearchfuture.com/sample_request/8633 Regional AnalysisThe market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.The somatostatin analogs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.The Western European market has further been divided as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.The somatostatin analogs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.Due to the rising per capita healthcare expenditure and growing awareness towards the treatment of acromegaly and NETs, the market in Asia-Pacific is expected to grow at a significant rate during the forecast.
Market HighlightsCarcinoid tumor is a type of the neuroendocrine tumor.The most common site of carcinoid tumors is the GI (gastrointestinal) tract and the lungs.However, it can also be developed in pancreas, testicles, and ovaries.According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract.However, lack of awareness, high treatment cost and related side effects may hamper the market growth during the forecast period.The serology segment is sub-segmented into blood test, urine test, molecular test, and others.
Global Appendiceal Cancer Treatment Market size was valued US$ XX Bn.in 2019 and the total revenue is expected to grow at CAGR of 4% from 2020 to 2027, reaching nearly US$ XX Bn.The report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.Definition:Appendiceal Cancer is the cancer of the appendix which is an organ connected to the colon at the beginning of the large intestine.It is often discovered during surgery for appendicitis or due to acute pain in the appendix.Market Dynamics:The function of the appendix is not known but it is said to help with the immunity as it stores good bacteria.The increased awareness about the severity of appendiceal cancer and its corresponding treatments especially the targeted therapies and other innovative therapies along with the support of the government schemes are expected to contribute to the growth of the global appendiceal cancer treatment market.In June 2019, Pfizer Inc. announced to acquire BioPharma Inc. to foster growth in the treatment segment.Market Segmentation:Based on the type, neuroendocrine tumors are the most commonly found among appendiceal cancer and are generally discovered or diagnosed after the appendix removal surgery.These tumors are more among the women aged above forty years.
A number of factors, such as increasing incidence of pancreatic cancer, availability of a limited number of drug therapeutic options for the treatment of advanced pancreatic neuroendocrine tumors, and poor diagnosis rate in the early stages of pancreatic cancer are driving the demand of sunitinib malate in the treatment of pancreatic cancer.Also, the overall number of patients who are eligible for taking sunitinib malate is expected to grow at a high CAGR during the forecast period.The Sunitinib Malate Market for pancreatic cancer is projected to reach USD 76.7 Million by 2021, at a CAGR of 13.9% from 2016 to 2021.Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194614514In this report, the market is segmented into seven country-level segments, namely, the U.S., Germany, France, the U.K., Italy, Spain, and Japan.The U.S. is expected to dominate this market primarily due to the higher number of patients suffering from pancreatic cancer in the country.However, the market in the U.K. is expected to witness the highest growth rate during the forecast period.This report contains detailed analysis of the sunitinib malate market for pancreatic cancer in terms of epidemiology, number of drug-treated patients suffering from pancreatic neuroendocrine tumors (pNET), percentage of patients eligible for taking sunitinib malate, penetration of sunitinib malate in pNET patients, number of pancreatic cancer patients, incidence rate of pancreatic cancer, 5-year survival rate of pNET patients, penetration of drug therapy in pancreatic cancer treatment, and trends in the adoption of sunitinib malate.Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=194614514This report also includes pricing analysis of sunitinib malate in all G7 countries and year-on-year market size of sunitinib malate for pancreatic cancer from 2010 to 2021.
The Somatostatin Analogs Market applications by MRFR Research Report Forecast 2020 is a valuable source of insightful data for business strategistsGlobal Somatostatin Analogs Market Research Report, By Types (Octreotide, Lanreotide, and Pasireotide), By Applications (Neuroendocrine Tumor (NET), Acromegaly and others), By Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2025  Also Read -  https://www.medgadget.com/2020/05/ophthalmic-equipment-market-updates-during-the-coronavirus-outbreak-2020-swot-analysis-of-leading-players-and-industry-key-factor-by-2023.htmlMarket HighlightsAccording to MRFR analysis, Somatostatin Analogs Market is expected to register a CAGR of 6.8% during the forecast period of 2019 to 2025 and is anticipated to reach USD 8,640 Million by 2025.The growth of the global somatostatin analogs market is driven by various factors such as increasing research & development activity in the somatostatin analogs market and increasing numbers of players involved in the development of generic versions of somatostatin analogs.Some of the key companies operating in this market are Nodysis Pharma, United Biotech, Wockhardt, Neiss, Sun Pharma, and Ferring Holding SA, among others.In addition, the rising incidence rate of the NETs; and increasing efforts by government bodies and public and private organizations to increase awareness about Acromegaly are some of the other factors for the growth of the somatostatin analogs market.Regional AnalysisThe market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas is expected to be the largest market owing to the increased awareness about NET’s and high per capita disposable incomes.The European somatostatin analogs market is the fastest-growing market, and it has been categorized as Western Europe and Eastern Europe.The Western European market has further been divided as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
Market OverviewThe Global Prostate Cancer Diagnostics Market is expected to grow at a high CAGR during the forecasting period (2020-2027).Prostate cancer begins when cells in the prostate gland start to grow out of control.Some other types of cancer that can start in the prostate include small cell carcinomas, neuroendocrine tumors, transitional cell carcinomas, and sarcomas.Some of the new test-launched by major players are:On December 29th, 2019, Anixa Biosciences, Inc. commercially launched the Cchek Prostate Cancer Confirmation test (Cchek PCC)— which utilizes artificial intelligence (AI), flow cytometry, and liquid-biopsy technology to detect prostate cancer was commercially launched.In July 2019, MDNA Life Sciences has launched the Mitomic® Prostate Test (MPTTM), the world’s most accurate blood test to determine whether a man does or does not have prostate cancer that requires treatment (clinically significant prostate cancer1).The Prostate-Specific Antigen (PSA) Test Market is expected to grow at a high CAGR during the forecasting period (2020-2027).Prostate-specific Antigen (PSA) is a protein produced by prostate cells and the PSA test is performed to diagnose prostate cancer (PCa) in men and for follow-up post-treatment to check if cancer relapses.Medicare and several private insurers provide coverage for an annual PSA test for all Medicare-eligible men aged 50 and older.It has more market value in the countries with a high prevalence rate (Western) and low prevalence rate (Asian), as PSA is used globally for the early detection/screening of prostate cancer.
Market OverviewThe Global Neuroendocrine Tumor Treatment Market is expected to grow at a CAGR of 10.4% during the forecasting period (2020-2027).The neuroendocrine tumor is a rare tumor that arises from the specialized body cells, called neuroendocrine cells.Download free sample: https://www.datamintelligence.com/download-sample/neuroendocrine-tumors-treatment-market Market DynamicsThe major driving forces are the increasing prevalence of neuroendocrine carcinoma, technological advancements, rising awareness among people, and the growing number of government initiatives.The prevalence of Neuroendocrine tumors is increasing across the globe, though being a rare disease as it is reported that more than 12,000 people are found to be affected by neuroendocrine tumors every year in the US.Therefore the increasing prevalence of neuroendocrine tumors helps in the adoption rate of the drugs for the treatment of this rare disease.The presence of ongoing research and development activities is expected to drive the market growth.For instance, few ongoing clinical trials include RAD 001 to treat advanced midgut NETs, Lanreotide Autogel for non-functional tumors, and NET-01 chemotherapy for the pancreatic tumors.Also, ongoing R activities in detection techniques, like Ga labeled radionucleotide therapies and the radiofrequency ablation technique, are the key factors driving the demand market.Below is one of the huge promising pipeline for neuroendocrine tumor treatment, which is expected to boost the market growth.The presence of increasing investments by government organizations is expected to drive the market growth.Such awareness programs also help vendors to understand opportunities in the current market scenario and invest in research to develop new therapies.However, the high cost of development and the onset of side effects are expected to hinder the market growth.The onset of side effects is likely to hamper the growth of the market over the forecast period.
The global thyroid gland disorder treatment market represents a highly competitive and fragmented landscape.This is mainly due to the presence of numerous small and large players in the market, says Transparency Market Research.These players are relying on several strategies such as partnership agreements, regional expansions, brand awareness activities, and increase product profiliration in order to gain a competitive edge in the market.In addition, increasing FDA approval of novel drug patent for the treatment of thyroid gland disorder treatment market is expected to fuel rivalry among players in the coming years.In june 2018,  Hutchison China MediTech Limited, a key players in the global throid gland disorder treatment market has  initiated a Phase Ib/II proof-of-concept study of sulfatinib in pancreatic neuroendocrine.Once developed and successfully tested the drug is expected to treat tumors and biliary tract cancer efficiently.This is expected to fuel tyroid gland disorder market in the coming years.Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=3113In the same year, another player called AmpliPhi Biosciences Corporation presented a AB-PA01 Bacteriophage Therap.
Global thyroid cancer drug market is rise gradually to an estimated value of USD 2404.8 million by 2026 registering a CAGR of 24.3% in the forecast period of 2020-2026.Thyroid cancer is also known as thyroid nodules is a cancer occur in thyroid gland and can spread to other parts of the body and about 90% of all thyroid cancers are benign.Key Market Players: Global Thyroid Cancer Drug MarketFew of the major competitors currently working in the thyroid cancer drug market are Mylan N.V., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Jerome Stevens Pharmaceuticals, Inc, Baxter, Abbott, Celgene Corporation, AstraZeneca, GlaxoSmithKline plc, Eisai Co., Ltd, Takeda Pharmaceutical Company Ltd, Biovista, Cytori Therapeutics Inc, Bayer AG, Novartis AG, Bio-Path Holdings, Inc, Vascular Biogenics, and few among others.Download exclusive PDF sample [email protected] https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-thyroid-cancer-drug-market Segmentation: Global Thyroid Cancer Drug MarketBy Type (Papillary thyroid cancer, Follicular thyroid cancer, Hurthle cell cancer, Medullary thyroid cancer (MTC) and Anaplastic thyroid cancer)By Drug Type (Thyroid desiccated, Sorafenib, Thyrotropin alfa, Vandetanib, Doxorubicin, Cabozantinib, Lenvatini, Sodium iodide I-131, Dabrafenib, Trametinib and Others)By Route of Administration (Oral, Injectable and Others)By Treatment (Medication, Chemotherapy, Radioactive iodine (radioiodine) therapy, Hormone therapy, and Surgery)By End- users (Hospitals, Homecare, Specialty Clinics, Others)By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)Competitive Analysis: Global Thyroid Cancer Drug MarketGlobal thyroid cancer drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.The report includes market shares of thyroid cancer drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.Market DriversIncrease in prevalence rate of neuroendocrine tumor worldwideAccelerating demand of treatment and novel therapiesRising awareness about treatment and technological advancement is driving the growth of marketIncreases cases of obesity and adopting unhealthy life styleMarket RestraintsEffective treatment is either unavailable or unaffordablePatent expiry of the patented drugs and introduction of generic version of branded drugs is expected to restrain the growth if the marketInadequate awareness about thyroid cancer treatment in some developing countriesSpeak to Analyst @ https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-thyroid-cancer-drug-market Reasons to Purchase this ReportCurrent and future of global thyroid cancer drug market outlook in the developed and emerging marketsThe segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast periodRegions/Countries that are expected to witness the fastest growth rates during the forecast periodThe latest developments, market shares, and strategies that are employed by the major market playersAbout Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches.We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.Contact:Data Bridge Market ResearchUS: +1 888 387 2818   Related Reports:substance abuse and addiction treatment marketStem Cell Therapy Market
Theranostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027Global Theranostics Market: An OverviewTheranostics is a new field of medicine which relies on targeted therapies to conduct specific targeted tests.The key concern in the therapeutics involve patient centric care with the help of more personalised and precise approach.The technique relies on the use of diagnostic and therapeutic applications to form a single agent.The growing incidences of cancers, and increasing need for a combination of therapies for cancers are expected to drive considerable growth for the theranostics market in the near future.Get an Idea about the Offerings of Our Theranostics Market Report from this Brochure Theranostics Market: Notable DevelopmentsThe FDA has approved Mayo Clinic’s new facility in Florida.The facility aims to provide positron emission tomography radiochemistry.The facility will also conduct various theranostics which are expected to aid help patients with metastatic neuroendocrine tumours.
Global Connected Drug Delivery Devices Market was valued US$ 172.43 Mn in 2018 and is expected to reach US$ XX Mn by 2026, at a CAGR of XX % during a forecast period.Self-administration of drugs through the usage of pre-filled syringes is one of the ways that can help patients to save the fees given to a caregiver.Additionally, limited knowledge and adoption rate among patients to hinder growth rate.The connected drug delivery devices market is majorly segmented into product, end-user, technology, disease indication type, treatment type, and region.In terms of disease indication type segment connected drug delivery devices market is categorized into gastric neuroendocrine tumours, lung neuroendocrine tumours, pancreatic neuroendocrine tumours, and appendiceal neuroendocrine tumours.On the basis of the end-user, the healthcare providers segment led the market with a revenue share and is expected to witness a lucrative market growth during forecast period due to increasing cases of diabetes, Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease, and other chronic diseases are anticipated to create the need for efficient health record systems.
Four years ago I coughed up blood.I saw an ear, nose and throat specialist and an oncologist in Corpus Christi, Texas, who suggested that perhaps I avoid tortilla chips, as I’d probably just cut my trachea eating. No big deal. A year later I got knocked up in a flurry of Hurricane Harvey tragedy excitement, which was pretty great, until I developed a cough so violent I vomited constantly and could hardly eat, drink or gain weight.The same ENT told me that there was nothing he could do ― after all, this was “what we sign up for when we become parents” and I’d probably be fine once I had the baby.I wasn’t.I never stopped coughing. All day, all night. Fast forward nine months and I developed a pneumonia I couldn’t shake while my son struggled with the knock-on effects of what turned out to be a misdiagnosed lung cancer. I must have missed the cancer sign-up sheet.Last May, a plucky pulmonologist diagnosed me with neuroendocrine cancer of the lung ― a rare disease that he insisted was the jackpot of malignant lung cancers.“It’s hardly cancer!” he told me. “It grows so slow, it’s Cancer Lite. Definitely the lung cancer you want to get. Definitely.”Was it really? I wondered, squirming in my 1990s nausea-patterned chair. Wasn’t not getting cancer the jackpot you wanted to hit? No matter. The doctor went on.“This is nothing. You cut out the lung. Bam, you’re back to your regular life.”I couldn’t quite integrate this knowledge with the facts of my regular life: I had a 10-month-old son, a 5-year-old daughter. I was 36, a nonsmoker, an obnoxious consumer of organic green peppers who religiously held her breath when driving past the local oil refineries three miles from our home. “What are you doing, Mama?” my daughter had asked years ago with fear and disgust. “Saving the life of your unborn half-fish, half-foetus brother!” I gasped after we careened past Refinery Row.But now, there it was, a tumour the size of a small city wedged smugly in my left bronchus. Mein Klein Corpus Christi.After my diagnosis came the referral to MD Anderson Cancer Center in Houston, a steady drip of doctors’ appointments, blood and breathing tests. Then surgery, then recovery. For me, these three years were 8% of my life. For my daughter they were 60% of her life. For my son, 100%.Between my diagnosis and my lung surgery, I had one month to recover from pneumonia, prepare myself, and prepare my children. I thought I’d have years to give my children all my stories, all my experiences. Suddenly I had 720 hours ― there was no time for the comprehensive Western canon, or the compendium of my personal misadventures. Instead, I recorded myself reading Matilda and Pippi Longstocking. I played 99 Luftballoons on repeat while my daughter and I danced in the kitchen, again and again and again. I filmed myself singing my son to sleep in our ugly brown armchair ― to market, to market to buy a fat pig ― smiling at him snuggled in his carrier while we walked up and down the street and he laughed at the wind on his cheeks ― home again, home again, jiggity jig. All this would remain if I did not.My husband said I needed to get stronger, so I started running again. Down the street from my house, past the big Baptist church and over Ocean Drive. It hurt. I’d cough, my tumour pressing too hard into my bronchus, and my lungs would spasm. I’d keep going. At the top of the hill leading down to the hotels, I’d see myself scooping up my son in one arm and my daughter in the other. I would look out over our few skyscrapers and feel myself sprinting over their rooftops, my children warm and safe in my arms as we left this city, this sickness behind us. I will save you. I will carry you as far as I can go, and then a little farther.Between my diagnosis and lung surgery, I had one month to recover from pneumonia, prepare myself, and prepare my children. I thought I’d have years to give my children all my stories, all my experiences. Suddenly I had 720 hours ― there was no time for the comprehensive Western canon, or the compendium of my personal misadventures.On the morning of my lung surgery I was at my parents’ sprawling one-story house in the suburbs of Houston. It was 5am. I’d slept maybe two hours. The house was dark and seemed uninhabited, framed somehow. The blue and brown tile floors, the beige walls: here was a house where people lived, and now I was leaving it to go, well, elsewhere. My body would be on a table at MD Anderson, my lungs in the hands of my surgeon, but my mind, my soul that had, up until this point, been solely the province of my husband and my children ― where was that going? I felt tentative, apart, as if wires had been stuck through my arms and legs. I didn’t know whether this was fear or something different, something prior or adjacent to life.I gently opened my sister’s door to kiss her goodbye. My daughter was snoring next to her, her body small under the pea green cover, her bangs crooked and perfect in a way I couldn’t focus on if I was going to be able to leave her. She looked so unprotected, so alone. Was she hot or cold? Did she need another cover, or should I take this one off?I kissed my sister’s sweaty forehead and she stirred to hug me. I kept looking at my daughter. Her body, not mine; her body, not mine. She would stay here. I would go away. The wires in my arms started to sting and I walked out of the room. I hadn’t kissed my daughter. I hadn’t touched her ― I couldn’t.My son slept in the guest room next to my sister’s. The door was shut. I paused in the dark hallway, scrunched my toes on the faded maroon rug. Again my arms ached, and again I walked away.When they wheeled me off to surgery the last thing I said to my husband was to kiss the kids for me, every day, please. People started pushing me away from my husband, away from my children. “Please,” I whispered, “I didn’t kiss them goodbye.”If I didn’t make it out of surgery, who could ever love my children as I had? The world that I had found so strange, so beautiful — who would guide them through it? Who would hold their hands?I don’t remember waking up, but I do remember a figure next to me gently laughing and patting my hand, “She’s fine. She’s on her way here.” My daughter — I was asking if my daughter was okay. My logic was frantic, groping, inverted: if my daughter was okay, then I must be alive. I must have survived.Things got grim after surgery. Breathing, walking, sleeping ― it all hurt, like knives in my lungs, like a rusted birdcage in my chest, like a hunter inside me I could not escape. For two months I couldn’t lift more than 10 pounds; I couldn’t hold my son. I became completely separate from my children. Were they fed? Clothed? Loved? I didn’t know; I didn’t consider these things.My daughter wouldn’t sleep, she put gum in her cousin’s hair, emptied out all the toothpaste. My son stopped eating. He would cry and he would whimper but he wouldn’t eat. At one point I stumbled out of my bedroom into the kitchen where my mom was holding my son, trying anything to get him to take one bite of food. I walked over and put the spoon of watery baby oatmeal in his mouth. He ate it, then another, then another. I fumed at my mother for doing it wrong. Couldn’t any of these people just feed a baby? Couldn’t they do it just like me?My son twisted his torso toward me, reached out his arms. I can’t take you, I can’t hold you. I closed my eyes and walked back into my bedroom.My body had been their home, and now even I could hardly live there.Two weeks after my surgery, a tender-hearted friend dropped my son. I was sitting nearby and managed to catch him just before his head hit the floor. I sobbed so hard after that I was sure my chest tube wound would split. It didn’t.As long as I was sick, my children couldn’t be healthy ― it was that simple. My son learned not to reach for me, my daughter learned how to make her own toast ― these things, these small things, were my kids getting ready for a world without me? That little girl snoring under the pea green comforter, could I go back to her? Cut all this out, fold the olive ribbon of time back together and go home to the little girl who had been good, the little girl who had been mine?I found a video on my phone from a month after my surgery. My daughter and I are at the beach, and it’s an ugly beach ― grimy sand, murky water, oil rigs dotting the distant sandbars. My daughter is skipping around the camera, around me. She’s wearing a bright blue shirt with a picture of a cherry red schoolhouse, and her hair is braided. Two little French plaits tightly wound at the top of her head and then frizzing out marvellously below. The waves crash around her small bare feet. A crane stands still on a cement wall just past us. My daughter darts a few feet ahead and shouts, “Wind and seashells ... today!” She jumps briefly into the waves, then out, then cocks her head to a horizon I’m not looking at and smiles. Just barely. A smile only a mother would see.She was going to be okay. I was going to be her mother again. In fits and starts and slowly now, I could come back to her as I came back to my own life.Two months later I could hold my son again. He learned to turn back my way when he was hungry or tired or scared. He would crawl and then walk toward me, his mother.Precedent tells me I’m now supposed to say we found joy. We found meaning. We found a sublime sort of redemption in the ugliness and pain of it all. But that isn’t at all what happened, or what continues to happen. We just made it, that’s all. We plodded through time, or time plodded through us. One day followed another, soon those days stacked up to weeks, and those weeks to months.Now my son runs, now my daughter poorly attempts to do basic math that is staggeringly boring. Life. It goes on whether or not I rejoice, whether or not I can rediscover the facile pleasure of complaining without sensing the distant heavy thud of a scythe or whatever it is death now wields (Reopening orders? A ventilator?).It’s been a year since my surgery. While there are treatments for neuroendocrine cancer, there’s still no cure for it. Should the cancer cells that spread to my lymphovascular system decide to organise elsewhere, I’ll undergo another surgery, shedding bits of myself like little unwanted Horcruxes. For now, the doctors watch my lungs, and I reassemble the pick-up sticks of my life.As long as I was sick, my children couldn’t be healthy ― it was that simple.When I came back from Houston after my last CT scan in January, I took my kids to the mall, my daughter’s favorite place. I used to find trips to the mall synonymous with existential dread, and they certainly still are, but this time, somewhere between the Sbarro pizza and the bathrooms, the dread was mixed with a bewildering ecstasy.I picked my son up out of his stroller and held my daughter’s hand. I squeezed them both. None of us made a sound as we stood together amid the ebb and flow of the pizza line that we, a small band of survivors, could watch from a new distance, a further orbit. We had brushed an edge, an unholy terror, and now we were somehow apart from the people all around us who didn’t know how lucky we were just to touch each other.I wanted to say all this to my son and daughter, to tell them that I am still your mother, and even though we carry this cancer with us, and even though I know you’re scarred where no one else can see, I’m still yours. I’m still here. I have carried you over the rooftops, I have folded up the ribbon of time, and now we are back together.But I didn’t say anything. I picked my daughter up, balancing her on the hip opposite my son. A bird squeaked above us. “Buh, buh,” my son babbled. “Bird!” my daughter shouted. “Bird!” We all tilted our heads upward and watched as a sparrow flitted across the steel beams of the Sbarro. I squeezed them both, held their small bodies close to mine.“Yes, that’s a bird,” I said. I closed my eyes and breathed in as deeply as I could.The grassy smell of my children’s hair, the doughy warmth of their arms and legs, the stench of cheese, a bird chirping in the mall rafters: jackpot. On the far shore of sickness, home.Sarah McClung is a writer recovering from cancer while raising her two small children. This article first appeared on HuffPost Personal.Have a compelling personal story you want to tell? Find out what we’re looking for here, and pitch us on [email protected] from HuffPost UK Personal This Is What It’s Like To Be A Paramedic On The Coronavirus Frontline As A Mum In Lockdown, My Social Life Has Never Been Better. What Happens Now? I Knew Miscarriage Was Lonely. Then I Lost My Pregnancy In Lockdown
Global Connected Drug Delivery Devices Market was valued US$ 172.43 Mn in 2018 and is expected to reach US$ XX Mn by 2026, at a CAGR of XX % during a forecast period.Global Connected Drug Delivery Devices MarketRising preference for injectable drug delivery is anticipated to drive the market for antiseptic drugs globally.Self-administration of drugs through the usage of pre-filled syringes is one of the ways that can help patients to save the fees given to a caregiver.Additionally, limited knowledge and adoption rate among patients to hinder growth rate.The connected drug delivery devices market is majorly segmented into product, end-user, technology, disease indication type, treatment type, and region.In terms of disease indication type segment connected drug delivery devices market is categorized into gastric neuroendocrine tumours, lung neuroendocrine tumours, pancreatic neuroendocrine tumours, and appendiceal neuroendocrine tumours.Further, connected drug delivery devices market based on treatment type includes somatostatin analogs, targeted therapy, and chemotherapy.On the basis of the end-user, the healthcare providers segment led the market with a revenue share and is expected to witness a lucrative market growth during forecast period due to increasing cases of diabetes, Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease, and other chronic diseases are anticipated to create the need for efficient health record systems.In terms of technology, Bluetooth segment led the market with the XX % of share market and is expected to witness lucrative growth during the forecast period, due to a large number of connected drug delivery systems work with Bluetooth as it is easily available and cheaper as compared to other technologies.However, other technologies segment is expected to emerge as the fastest-growing segment in the next few years.In terms of region, North America accounted for the XX % market share and is expected to lead the market over the forecast period, owing to quick adoption of latest technologies and devices, high per capita healthcare expenditure, and raising awareness regarding the adverse effects of non-adherence to medication.The objective of the report is to present comprehensive analysis of Global Connected Drug Delivery Devices Market including all the stakeholders of the industry.
Market Research Future published a half-cooked research report on global carcinoid tumor market.Carcinoid Tumor Market HighlightsCarcinoid tumor is a type of the neuroendocrine tumor.The most common site of carcinoid tumors is the GI (gastrointestinal) tract and the lungs.However, it can also be developed in pancreas, testicles, and ovaries.According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract.The serology segment is sub-segmented into blood test, urine test, molecular test, and others.
More

Top